NCT00004930View on ClinicalTrials.gov

Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 1999

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions
Lung CancerMetastatic Cancer
Interventions
DRUG

doxorubicin hydrochloride

Trial Locations (2)

10021

Memorial Sloan-Kettering Cancer Center, New York

43210

Arthur G. James Cancer Hospital - Ohio State University, Columbus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00004930 - Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases | Biotech Hunter | Biotech Hunter